Bio Green Med Solution, Inc.

BGMS

HealthcareMedical - PharmaceuticalsNASDAQ

$0.90

Market Cap: $1.97M

Bio Green Med Solution, Inc. (BGMS) Valuation Summary

Updated Apr 14, 2026 22:14

Model	Range	Fair Value	Upside
▸ Discounted Cash Flow
Revenue DCF 5Y	$7,825.03 – $17,394.56	$10,868.64	+1044961.4%
Revenue DCF 10Y	$6,398.39 – $13,054.47	$8,550.13	+822028.1%
▸ Trading Multiples
EV/Revenue	$1.76 – $8.97	$1.71	+64.7%

Valuation History

DCF Analysis

Bio Green Med Solution, Inc. (BGMS) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$8,550.13

Market Price

$0.90

Upside / Downside

+949492.4%

Verdict

Undervalued

Using a Revenue DCF model with operating margin convergence from -1128.1% to a target of 13.3% over 5 years, discounted at a WACC of 8.5%, Bio Green Med Solution, Inc. (BGMS) has an intrinsic value of $8,550.13 per share (range: $6,398.39 – $13,054.47).

Key Assumptions

Current Operating Margin

-1128.1%

Target Operating Margin

13.3%

WACC

8.5%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

0.5%

Target CapEx/Rev

11.0%

D&A/Revenue

7.3%

Tax Rate

21.0%

Operating margin fades linearly from the current level to the industry target over the 5-year projection. CapEx intensity fades from the historical average to a maintenance level (D&A × 1.5). Tax is only applied when operating income is positive (NOL shield).

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	0	-86.6%	-899.8%	-1	-1	0	(0)	-5	4	4
2027	81	80482.0%	-671.5%	-541	-541	6	(2)	-2,637	2,100	1,857
2028	118	46.5%	-443.2%	-523	-523	9	(4)	-1,229	710	578
2029	154	30.0%	-214.9%	-330	-330	11	(7)	-1,161	835	627
2030	200	30.0%	13.3%	27	21	15	(11)	-1,509	1,533	1,061
2031	256	28.3%	13.3%	34	27	19	(17)	-1,851	1,879	1,198
2032	316	23.2%	13.3%	42	33	23	(25)	-1,950	1,981	1,164
2033	373	18.2%	13.3%	50	39	27	(33)	-1,880	1,913	1,036
2034	422	13.1%	13.3%	56	44	31	(42)	-1,603	1,637	816
2035	456	8.1%	13.3%	61	48	33	(50)	-1,114	1,145	526

Enterprise Value Bridge

Sum of PV(FCFF)8,868

Terminal Value (Gordon Growth at 3.0%)21,346

PV of Terminal Value9,811

Enterprise Value18,679

(–) Net Debt-4

Equity Value18,683

(÷) Shares Outstanding2

Fair Value per Share$8,550.13

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.3%	10.3%	13.3%	16.3%	19.3%
6.5%	$12672	$12768	$12863	$12959	$13054
7.5%	$10099	$10171	$10243	$10314	$10386
8.5%	$8436	$8493	$8550	$8607	$8664
9.5%	$7268	$7315	$7361	$7408	$7454
10.5%	$6398	$6437	$6476	$6515	$6554

Current price: $0.90. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at -3276.6% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Bio Green Med Solution, Inc. (BGMS) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$10,868.64

Market Price

$0.90

Upside / Downside

+1206990.2%

Verdict

Undervalued

Using a Revenue DCF model with operating margin convergence from -1128.1% to a target of 13.3% over 5 years, discounted at a WACC of 8.5%, Bio Green Med Solution, Inc. (BGMS) has an intrinsic value of $10,868.64 per share (range: $7,825.03 – $17,394.56).

Key Assumptions

Current Operating Margin

-1128.1%

Target Operating Margin

13.3%

WACC

8.5%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

0.5%

Target CapEx/Rev

11.0%

D&A/Revenue

7.3%

Tax Rate

21.0%

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	0	-86.6%	-899.8%	-1	-1	0	(0)	-5	4	4
2027	81	80482.0%	-671.5%	-541	-541	6	(4)	-2,637	2,098	1,856
2028	118	46.5%	-443.2%	-523	-523	9	(8)	-1,229	706	575
2029	154	30.0%	-214.9%	-330	-330	11	(14)	-1,161	828	622
2030	200	30.0%	13.3%	27	21	15	(22)	-1,509	1,523	1,054

Enterprise Value Bridge

Sum of PV(FCFF)4,111

Terminal Value (Gordon Growth at 3.0%)28,375

PV of Terminal Value19,634

Enterprise Value23,745

(–) Net Debt-4

Equity Value23,749

(÷) Shares Outstanding2

Fair Value per Share$10,868.64

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.3%	10.3%	13.3%	16.3%	19.3%
6.5%	$17187	$17239	$17291	$17343	$17395
7.5%	$13289	$13328	$13368	$13408	$13447
8.5%	$10805	$10837	$10869	$10901	$10932
9.5%	$9085	$9112	$9138	$9165	$9191
10.5%	$7825	$7848	$7870	$7893	$7915

Current price: $0.90. Green = undervalued, Red = overvalued.

Working Capital Assumption

Trading Multiples

Fair Value

$1.71

Market Price

$0.90

Upside / Downside

+90.2%

Verdict

Undervalued

Using the industry peer median EV/Revenue multiple (trailing + forward), Bio Green Med Solution, Inc. (BGMS) has a fair value of $1.71 based on 3 comparable companies in the Medical - Pharmaceuticals industry.

EV/Revenue Valuation — Medical - Pharmaceuticals

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
Bio Green Med Solution, Inc.BGMS	2	-2.1x	-29.0x
Movano Inc.MOVE	12	21.5x	3.9x
60 Degrees Pharmaceuticals, Inc.SXTP	2	0.5x	0.5x
Venus Concept Inc.VERO	1	0.6x	0.4x
Industry Median		0.6x	0.5x
(*) Revenue		1	0
= Enterprise Value		0	0
(-) Net Debt		-4	-4
Equity Value		4	4
(/) Outstanding shares		2	2
Fair Price		$2	$2

Selected Fair Value (avg of trailing + forward)

$1.71

+90.2%

Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.

Model

Range

Fair Value

Upside

▸ Discounted Cash Flow

Revenue DCF 5Y

$7,825.03 – $17,394.56

$10,868.64

+1044961.4%

Revenue DCF 10Y

$6,398.39 – $13,054.47

$8,550.13

+822028.1%

▸ Trading Multiples

EV/Revenue

$1.76 – $8.97

$1.71

+64.7%

DCF Analysis

Bio Green Med Solution, Inc. (BGMS) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$8,550.13

Market Price

$0.90

Upside / Downside

+949492.4%

Verdict

Undervalued

Key Assumptions

Current Operating Margin

-1128.1%

Target Operating Margin

13.3%

WACC

8.5%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

0.5%

Target CapEx/Rev

11.0%

D&A/Revenue

7.3%

Tax Rate

21.0%

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	0	-86.6%	-899.8%	-1	-1	0	(0)	-5	4	4
2027	81	80482.0%	-671.5%	-541	-541	6	(2)	-2,637	2,100	1,857
2028	118	46.5%	-443.2%	-523	-523	9	(4)	-1,229	710	578
2029	154	30.0%	-214.9%	-330	-330	11	(7)	-1,161	835	627
2030	200	30.0%	13.3%	27	21	15	(11)	-1,509	1,533	1,061
2031	256	28.3%	13.3%	34	27	19	(17)	-1,851	1,879	1,198
2032	316	23.2%	13.3%	42	33	23	(25)	-1,950	1,981	1,164
2033	373	18.2%	13.3%	50	39	27	(33)	-1,880	1,913	1,036
2034	422	13.1%	13.3%	56	44	31	(42)	-1,603	1,637	816
2035	456	8.1%	13.3%	61	48	33	(50)	-1,114	1,145	526

Enterprise Value Bridge

Sum of PV(FCFF)8,868

Terminal Value (Gordon Growth at 3.0%)21,346

PV of Terminal Value9,811

Enterprise Value18,679

(–) Net Debt-4

Equity Value18,683

(÷) Shares Outstanding2

Fair Value per Share$8,550.13

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.3%	10.3%	13.3%	16.3%	19.3%
6.5%	$12672	$12768	$12863	$12959	$13054
7.5%	$10099	$10171	$10243	$10314	$10386
8.5%	$8436	$8493	$8550	$8607	$8664
9.5%	$7268	$7315	$7361	$7408	$7454
10.5%	$6398	$6437	$6476	$6515	$6554

Current price: $0.90. Green = undervalued, Red = overvalued.

Working Capital Assumption

Trading Multiples

Fair Value

$1.71

Market Price

$0.90

Upside / Downside

+90.2%

Verdict

Undervalued

EV/Revenue Valuation — Medical - Pharmaceuticals

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
Bio Green Med Solution, Inc.BGMS	2	-2.1x	-29.0x
Movano Inc.MOVE	12	21.5x	3.9x
60 Degrees Pharmaceuticals, Inc.SXTP	2	0.5x	0.5x
Venus Concept Inc.VERO	1	0.6x	0.4x
Industry Median		0.6x	0.5x
(*) Revenue		1	0
= Enterprise Value		0	0
(-) Net Debt		-4	-4
Equity Value		4	4
(/) Outstanding shares		2	2
Fair Price		$2	$2

Selected Fair Value (avg of trailing + forward)

$1.71

+90.2%